The Dexcom G7 15 Day CGM system is a wearable sensor that continuously measures glucose levels and transmits readings every 5 minutes with no fingersticks or scanning required.

The new sensor — expected to launch in the second half of 2025 — will provide easier diabetes management for eligible users.

Dexcom has announced that the U.S. Food and Drug Administration has cleared its G7 15 Day Continuous Glucose Monitoring ...

If you're using a Dexcom G7 to monitor your blood sugar in real-time, you can now sync it to your Apple Watch for real-time ...

DexCom stock was on the rise Thursday after the maker of medical technology said it had received clearance from the U.S. Food ...

DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the FDA has cleared the Dexcom G7 15 Day ...

The US Food and Drug Administration has cleared the latest version to last 5 days longer than previously for adult users.

Dexcom has won a clearance from the FDA for its longest-lasting continuous glucose monitor, a 15-day version of its flagship ...

Dexcom (Nadsaq:DXCM) announced today that the FDA cleared its G7 15-day continuous glucose monitoring (CGM) system.

The U.S. Food and Drug Administration approved DexCom, Inc.’s (NASDAQ:DXCM) Dexcom G7 15-Day Continuous Glucose Monitoring System for people over 18 with diabetes. With an overall Mean Absolute ...

DexCom (DXCM) announced the FDA has cleared the Dexcom G7 15 Day continuous glucose monitoring system for people over the age of 18 with ...

Shares traded 8.5% higher at $72.55. The company, which focuses on glucose biosensing--which measures glucose levels in wearers--said that the Food and Drug Administration has cleared the Dexcom G7 15 ...